TransThera Sciences (Nanjing), Inc.
Research TransThera Sciences (Nanjing), Inc. (2617.HK) on Bullrun: market cap HKD 3.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2617.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 3.78B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 295.96M
- Free cash flow-CNY 253.68M
Valuation Snapshot
latest market cap is HKD 3.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 295.96M | -CNY 253.68M | n/a | -0.76 | CNY 415.41M | CNY 1.65M | CNY 416.38M |
| FY2024 | CNY 0 | -CNY 274.61M | -CNY 271.96M | n/a | -0.69 | CNY 569.51M | CNY 4.37M | CNY 525.03M |
| FY2023 | CNY 1.18M | -CNY 343.39M | -CNY 331.12M | 100.0% | -0.87 | CNY 496.63M | CNY 4.81M | CNY 783.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.78B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma;
ETFs that hold TransThera Sciences (Nanjing), Inc.
US-listed ETFs
TransThera Sciences (Nanjing), Inc. is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| BNY Mellon Emerging Markets Equity ETF (BKEM) | <0.01% | 0.11% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TransThera Sciences (Nanjing), Inc.'s market cap?
TransThera Sciences (Nanjing), Inc.'s market capitalization is HKD 3.78B.
What does TransThera Sciences (Nanjing), Inc. do?
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors.